Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infection
Biotech
Recce's synthetic gel treats skin infections in ph. 2
Recce’s synthetic anti-infective treated a range of skin infections in a mid-stage trial, setting the Australian biotech’s sights on a phase 3 trial.
James Waldron
Feb 19, 2025 8:39am
X4 scores a phase 3 win for immune deficiency disorder drug
Nov 30, 2022 10:45am
Could a single pill outsmart a tumor's resistance mechanisms?
Mar 29, 2021 10:00am
Gilead snaps ups German virology biotech MYR
Dec 10, 2020 8:55am
Takeda's maribavir hits phase 3 goal
Dec 4, 2020 8:47am
Finch nets $90M to push C. diff microbiome med toward FDA filing
Sep 17, 2020 7:00am
